Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

GeneDx Holdings (WGS) FCF Margin (2020 - 2025)

GeneDx Holdings (WGS) has disclosed FCF Margin for 6 consecutive years, with 14.58% as the latest value for Q4 2025.

  • On a quarterly basis, FCF Margin fell 1380.0% to 14.58% in Q4 2025 year-over-year; TTM through Dec 2025 was 3.34%, a 1267.0% increase, with the full-year FY2025 number at 3.34%, up 1267.0% from a year prior.
  • FCF Margin was 14.58% for Q4 2025 at GeneDx Holdings, down from 16.95% in the prior quarter.
  • In the past five years, FCF Margin ranged from a high of 3112.05% in Q2 2021 to a low of 237.81% in Q2 2022.
  • A 5-year average of 88.97% and a median of 61.15% in 2021 define the central range for FCF Margin.
  • Peak YoY movement for FCF Margin: crashed -334986bps in 2022, then surged 12702bps in 2023.
  • GeneDx Holdings' FCF Margin stood at 83.74% in 2021, then decreased by -27bps to 106.48% in 2022, then soared by 51bps to 52.0% in 2023, then surged by 99bps to 0.78% in 2024, then tumbled by -1779bps to 14.58% in 2025.
  • Per Business Quant, the three most recent readings for WGS's FCF Margin are 14.58% (Q4 2025), 16.95% (Q3 2025), and 4.01% (Q2 2025).